Back |
home / stock / cytx / cytx message board
Subject | By | Source | When |
---|---|---|---|
Yeah I expected some but this is pretty | KennyPro | investorshub | 02/04/2019 6:04:57 PM |
Mega Dilution announced. | hopester | investorshub | 02/04/2019 5:44:00 PM |
Again; very Good wishes on your hopes. | hopester | investorshub | 02/01/2019 2:19:29 PM |
Thanks for the good wishes......one thing for certain | KennyPro | investorshub | 02/01/2019 1:34:22 PM |
Good Luck 2 u. | hopester | investorshub | 02/01/2019 1:09:20 PM |
Welcome to the OTC....flippers never saw a pop | KennyPro | investorshub | 02/01/2019 12:48:56 PM |
Nice early pop. But then the disappointing drop. | hopester | investorshub | 01/31/2019 4:28:43 PM |
Great response...I hope to see them use this | KennyPro | investorshub | 01/31/2019 3:17:54 PM |
NEWS -- Cytori Cell Therapy Clinical Trial Results | Paulness | investorshub | 01/31/2019 2:02:26 PM |
Best of Luck! | hopester | investorshub | 01/30/2019 12:43:36 AM |
I own it now because the PPS is | KennyPro | investorshub | 01/29/2019 8:51:29 PM |
In what time? Years and Years? And what | hopester | investorshub | 01/29/2019 7:10:17 PM |
News, Short Squeeze, Breakout and More Instantly...
Cytori Therapeutics Inc. Company Name:
CYTX Stock Symbol:
NASDAQ Market:
Cytori Therapeutics Inc. Website:
AUSTIN, Texas, July 16, 2019 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (Nasdaq: CYTX) (the “company”) announced yesterday a new direction and identity. Since the beginning of 2019, the company has successfully evaluated and transformed its pipeline to place a stronger e...
SAN DIEGO, July 11, 2019 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ: CYTX) “the Company” will provide a live webcast to discuss its new company direction following two recent asset sales and highlight key anticipated milestones on July 15, 2019 at 4:30 PM Eastern Ti...
AUSTIN, Texas, July 01, 2019 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ: CYTX) today provided an update on the development of its proprietary drug, ATI-1123, based on recently obtained feedback from the United States Food and Drug Administration (FDA). ATI-1123 is a substantially...